C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 14/705 (2006.01) A61K 35/14 (2006.01) A61K 38/17 (2006.01) C07K 7/06 (2006.01) C07K 14/47 (2006.01) C07K 14/74 (2006.01) C12N 5/10 (2006.01) G01N 33/574 (2006.01) C07K 16/30 (2006.01)
Patent
CA 2186004
Tumor rejection antigens derived from MAGE tumor rejection precursors have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
Des antigènes de rejet des tumeurs dérivant de précurseurs de l'antigène MAGE de rejet des tumeurs ont été identifiés. Ces antigènes de rejet des tumeurs (TRAS) se fixent à la molécule d'HLA-A2 de la classe I de la CMH, et le complexe résultant stimule la production de clones de cellules T cytolytiques qui lysent les cellules apparaissant. Ces peptides et ces complexes peuvent servir à des fins de diagnostic et de traitement, ou d'immunogènes pour la production d'anticorps, ou de cibles pour la production de clones de cellules T cytolytiques.
Bastin Judy
Boon-Falleur Thierry
Coulie Pierre
Gajewski Thomas
Kast W. M.
Borden Ladner Gervais Llp
Ludwig Institute For Cancer Research
The Chancellor Masters And Scholars Of The University Of Oxford
University Of Leiden
LandOfFree
Isolated peptides derived from mage tumor rejection antigen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated peptides derived from mage tumor rejection antigen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated peptides derived from mage tumor rejection antigen... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1769513